Ministry of Industry and Information Technology Released List of China's Top 100 Enterprise of Pharmaceutical Industry in 2020; Enterprises of Lianyungang First Entered Top 5

On August 1st, the "2021 (38th) National Pharmaceutical Industry Information Annual Conference" hosted by China Pharmaceutical Industry Information Center opened in Jinan, Shandong Province. At the meeting, the List of China Top 100 Enterprises of Pharmaceutical Industry in 2020 was released. Enterprises in Lianyungang like Hengrui Pharma, Chiatai Tianqing and Hansoh Pharma ranked 4th, 15th and 32nd respectively. Among them, Hengrui Pharma once again refreshed the ranking of enterprises of Lianyungang in the list and entered the top five. At the same time, Hengrui Pharma, Hansoh Pharma, Chiatai Tianqing and Kanion Pharmaceutical also ranked first, third, fourth and seventh among the best industrial enterprises in China's pharmaceutical R & D product line, making Lianyungang the city with the largest number of listed enterprises among all the prefecture-level cities. According to the relevant scientific and technological personnel of the Municipal Bureau of Science and Technology, this list testify the popular words of “Jiangsu leads China in medical innovation, and Lianyungang contributes the most medical innovations to Jiangsu.” By virtue of scientific and technological innovation, the ranking of Lianyungang’s enterprises in the top 100 list has increased year by year and dominated the innovation list for many years, which shows that innovation is not only the lifeline to support the development of China's pharmaceutical industry, but also an important magic weapon to maintain the advantages of Lianyungang’s pharmaceutical industry.

It is known that the "Top 100 List of China's Pharmaceutical Industry" is ranked based on the annual report of China's Pharmaceutical Statistics. It is known as the wind vane of the development of China's pharmaceutical industry, which authoritatively reflects the economic operation of China's pharmaceutical industry. The evaluation of the “Best Industrial Enterprise in China's Pharmaceutical R & D Product Line" is based on the two aspects of drugs and enterprises through a comprehensive investigation of the product innovation dimension, layout dimension, development dimension, competition dimension, status dimension and enterprise characteristic dimension, leading dimension, coincidence dimension, dependence dimension and scale dimension of pharmaceutical enterprises. The experts of the comprehensive evaluation group shall give coefficient adjustment weight to the proportion of each dimension in the comprehensive evaluation, multiply it with the standard score, and obtain the comprehensive score of the enterprise after weighted calculation. The final ranking of enterprises is determined by the comprehensive score.

We have made unremitting and continuous innovation to create the miracle of Lianyungang. The pharmaceutical innovation in Lianyungang presents the wolf pack effect. As an economically underdeveloped region, Lianyungang’s pharmaceutical innovation has been leading the industry trend in the past decade. Taking Hengrui Pharma as an example, in 2020, Hengrui invested 4.989 billion yuan in R & D, accounting for 18% of revenue, ranking in the forefront of the national pharmaceutical industry. It has established R & D centers in the United States, Europe, Japan and China, forming an innovation pattern with its own strengths and complementary functions. Its core technical team has nearly 5000 global R & D personnel, including master and doctoral talents, returnees and core technical talents, which provides strong talent support for the high-quality development of the enterprise. In fact, such a case is not rare in Lianyungang. In 2020, the R & D investment of Hansoh Pharma accounted for more than 14% of the sales revenue, ranking in the forefront of the national pharmaceutical industry. After more than 20 years of continuous high-intensity R & D investment, Hansoh's R & D strength is stronger. At present, 5 Class I innovative drugs have come to market, more than 100 drugs are under research, and more than 20 innovative drugs have entered the clinical stage, forming a rich product pipeline. At the same time, R & D centers have been established in Shanghai, Lianyungang and other places to vigorously cultivate and introduce high-level technical talents, with a total of more than 1600 professional R & D personnel. Chiatai Tianqing and Kanion Pharmaceutical are not inferior in this regard. In 2020, the R & D cost of Chiatai Tianqing exceeded 2 billion yuan, accounting for more than 12% of the sales revenue. The company has more than 190 products under development, more than 80 innovative drugs and more than 40 biological drugs, forming a benign pattern of "launched generation, reserve generation and R & D generation". Kanion Pharmaceutical has long been in the forefront of domestic traditional Chinese medicine innovation and has a good product line. Its Guizhi Fuling Capsule is under the phase III clinical experiment in the United States and is expected to become a leader in the internationalization of Chinese traditional Chinese medicine. According to relevant statistical data, in 2020, the pharmaceutical industry above designated size will achieve an output value of 62 billion yuan, accounting for 22% of the total output value of industries in the city. The operating revenue is 55 billion yuan, accounting for 20% of the total operating revenue of the city. The profit is 15 billion yuan, accounting for 61% of the total profit of the city.

While enterprises adhere to innovation, Lianyungang has established a good policy environment. China Pharmaceutical Port has issued 15 opinions on the high-quality development. It has increased policy support from 15 aspects such as pharmaceutical varieties, public service platform and product internationalization. The "magnetic core effect" of platform agglomeration is becoming more and more obvious. According to the relevant person in charge of the Municipal Development Zone, Huaguo Mountain Medical Science Center has been established to build a systematic scientific and technological innovation platform and professional service system of China Pharmaceutical Port. We also establish an expert review mechanism for project entry to conduct professional evaluation on project access, and use area and preferential policies to ensure the maximum benefit of limited resources. The Measures for the Administration and Services for Enterprises Settled were issued to establish a professional service team to provide enterprises with all-round, whole process and all-weather professional services. In terms of investment guarantee, 5% of the fiscal revenue is allocated annually to support the innovation and entrepreneurship of enterprise teams in the pharmaceutical industry. For example, 24 million yuan will be awarded for Class I new drugs in the phase from R & D to industrialization. For industrialization projects, equipment subsidies of up to 20 million yuan will be given. In addition, we have paid close attention to the implementation of the policies that have been issued and worked to ensure the full implementation of related policies. In the past two years alone, we have reduced taxes for pharmaceutical enterprises by 1.89 billion yuan.